Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirapazamine - Teclison

Next Previous
X
Search
Drug Profile

Tirapazamine - Teclison

Alternative Names: NSC 130181; SR 259075; SR 4233; TATE; TEC-001; Tirazone; WIN 59075

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SRI International; Stanford Cancer Institute
  • Developer Merck Sharp & Dohme Corp.; SRI International; Teclison
  • Class Antineoplastics; Radiation-sensitising agents; Reducing agents; Small molecules; Triazines
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Colorectal cancer; Liver cancer; Non-small cell lung cancer
  • Discontinued Glioma; Head and neck cancer; Malignant melanoma

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Liver-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Intra-arterial, Infusion)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Non small cell lungs cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 14 Apr 2023 Pharmacodynamics data from the preclinical studies in cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top